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COMMENT

Urinalysis Drug Testing of Employees at

Will: The Need for Mandatory Standards
I.

INTRODUCTION

While urinalysis drug testing is still relatively new in the business
world, it has enjoyed a remarkable growth rate and can be expected
to affect most people at some point in their careers. Forty-three
percent of companies with 1,000 or more employees now have drug
testing programs,' and industry analysts estimate that by 1992, twentytwo million Americans annually will be required to submit to drug
tests as part of their job requirements. 2 Drug testing is fast becoming
a routine procedure in the employment context.
Given the strong support of both the government and general
public to fight the "War on Drugs," 3 this trend toward workplace
drug testing will likely continue. 4 Considering that more than fortythree percent of large companies are already utilizing urinalysis testing
in the workplace and the "drug hysteria" media campaign in Amer-

1. Molnar, Drug Testing: A Corporate Crackdown, 7 Bus. J. OF N.J. 105,
105 (1990).
2. Freudenheim, Booming Business: Drug Use Tests, The New York Times,
Jan. 3, 1990, at DI.
3. In this comment, the "war on drugs" refers to the increased governmental
and media attention given to America's illicit drug problem starting with the Reagan
administration in 1982. See Exec. Order No. 12,564, 3 C.F.R. 224 (1987), reprinted
in 5 U.S.C. § 7301 (Supp. V 1987) (calling for a "Drug-Free Workplace"); DrugFree Workplace Act of 1988, Pub. L. No. 100-690, Title V, Subpart D (1988), 102
Stat. 4304 (codified as amended at 41 U.S.C. §§ 701-702 (1990)). Commentators have
suggested that the government and media may have inflated the actual problem. See
Note, Survey on the Law on Employee Drug Testing, 42 U. MIAMI L. REV. 553, 561
(1988); Comment, Use and Abuse of Urinalysis Testing in the Workplace: A Proposal
for Federal Legislation Limiting Drug Screening, 35 EMORY L.J. 1011, 1066 (1986)
("blatant sensationalism" by media ignoring statistics).
4. A public opinion survey taken in 1987 showed 69%70 endorse drug testing in
the workplace. Steiber, Public Support of Drug Testing Increases, Hosp., Nov. 5,
1987, at 92.
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ica,5 it would be a futile point to advocate a total prohibition on drug
testing. Instead, this comment proposes that the Mandatory Guidelines
for Federal Workplace Drug Testing Programs, 6 developed by the
National Institute on Drug Abuse [hereinafter NIDA Guidelines], be
applied uniformly to all companies using drug testing. This would
allow drug testing to continue, while requiring companies engaging in
drug testing to follow certain minimum standards to ensure accurate
test results.
Section II of this comment explains the various drug tests available to employers. In addition, this section discusses the Federal
Guidelines which this paper proposes should be applied to any employer engaged in drug testing and summarizes the basic rights of
employers and employees. Part III explains the present status of the
law concerning drug testing in the employment context and analyzes
the problems inherent in applying it. Part IV will present this comment's proposal for changing the existing law as applied to employment drug testing, followed by a conclusion in Part V.
II.

COMPONENTS OF THE ISSUE

A knowledge of the existing tests, standards, and law is required
to fully understand the drug testing issue. This section will outline the
requirements that the NIDA Guidelines now impose on federal agencies' drug testing programs and explain the basic rights and doctrine
of law as applied to private employers. First, an initial outline of the
common drug tests in current usage is necessary.
A.

DRUG TESTING

Technology is rapidly advancing in the drug testing field, and
drug testing may now be performed with samples of hair, breath, or
saliva. 7 However, these procedures all have deficiencies at their present
state of refinement as compared to urinalysis and are not generally
5. See Comment, Use and Abuse of Urinalysis Testing in the Workplace: A

Proposal for Federal Legislation Limiting Drug Screening, 35 EMORY L.J. 1011, 1066

(1986) ("blatant sensationalism" by media ignoring statistical evidence that drug use
is dwarfed by alcohol abuse).
6. 53 Fed. Reg. 11,970 (1988) (guidelines published by Department of Health
and Human Services, National Institute on Drug Abuse requiring procedures to be
followed by all federal agencies in setting up their drug testing programs).
7. See generally K. ZEESE, DRUG TESTING LEGAL MANUAL § 2.03 (1989 &
Supp. 1990).
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used in the employment setting.' The discussion of this comment,

therefore, is limited to urinalysis drug testing, the drug testing technique in mass use by employers.9

Use of the term "drug" test in reference to urinalysis testing is
0
really a misnomer. What is normally being tested for are metabolites,
the inactive residue remaining after the body has processed the drug."'

This means that no urine detection system can measure "whether a
drug is present in the blood, nor does it reveal the time or quantity
of drug intake.' ' 2 The most any drug test can accomplish is to give
a "positive"'

3

result when a metabolite is present in the test subject's

urine.'
This positive result may indicate any one of three separate
inferences and does not justify the conclusion that the test subject is
4

a drug user. First, the subject may have recently been exposed to a
5
drug, which is possible through passive inhalation. Second, the

8. Research on these techniques appears promising, but is still in the early
stages. Drug testing of hair is slightly more refined, but has problems with passive
absorption (drugs entering the hair from the external environment). See id.
9. The fact that other areas of drug testing are rapidly developing lend support
to this comment's proposal to enact regulations in the form of the NIDA agency
regulations rather than to regulate by statute. NIDA is heavily involved in drug
research and will be better suited to adapt their regulations to new techniques that
become available (once reliable). A statutory solution would be much harder to adapt
and regulate.
10. Webster's defines metabolite as "a product of metabolism". WEBSTER'S
NINTH NEW COLLEGIATE DICTIONARY

745 (1983).

11. Morgan, Urine Testing for Abused Drugs: Technology and Problems, in

DRUG TESTING: PROTECTION

FOR SOCIETY OR A VIOLATION OF CIVIL RIGHTS?

34, 35

(1987).
12. Holden, Doctors Square Off on Employee Drug Testing, ScI., Nov. 6,
1987, at 744 (quoting George D. Lundberg, editor of the J. A.M.A.).
13. A positive drug test is one in which a metabolite was detected to be present

in a concentration above the threshold level designated to indicate a certain drug.
Black, Testing For Abused Drugs: A Primer for Executives, in DRUG TESTING:
PROTECTION FOR SOCIETY OR A VIOLATION OF CrwL RIGHTS? 26, 27 (1987). This

threshold level is a defined level chosen to reflect recent drug use. "Cutoff points
have been recommended in ... [NIDA Guidelines]. Unfortunately, private companies

are not required to follow these federal guidelines and many do not." McMillan,
urine screening: what does it mean?, in PROBLEMS OF DRUG DEPENDENCE 1989 206,
207 (1990).
14. See Holden, supra note 12, at 744. See generally manno, interpretation of
urinalysis results, in URINE TESTING FOR DRUGS OF ABUSE 54 (1986).
15. Hawks & Chiang, Examples of Specific Drug Assays, in URINE TESTING
FOR DRUGS OF ABUSE 84, 86 (1986) (passive inhalation of marijuana could result in
positive drug test, but may require very close contact with smoker such as in a car
or small room with poor ventilation).
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subject may have previously used the drug, although that person is
not necessarily presently impaired, and may have used the drug over
30 days previously.1 6 Finally, the test subject might have recently taken
medication or other substances that produce the same metabolites as
an illicit drug being tested for. This is very common considering that
various over-the-counter medications, poppy seeds, or prescription
medication can "cross react.""7
While many personnel managers would assume that a positive
urinalysis reveals a drug-impaired employee, it is merely an indicator
that metabolites are present and a problem may exist. A positive
urinalysis drug test result does not necessarily correlate to either recent
drug use of any kind, or present impairment due to drug use.'"
This does not imply that fairly conclusive evidence of drug use
cannot be obtained when drug test information is combined with
further in-depth testing and a background medical check.' 9 Ideally,
16. The length of time that a drug metabolite will show up in a urine sample
would depend on the drug in question, as the body has different metabolic rates for
each substance. It would also depend on the individual person's rate of metabolism.
Cocaine metabolites can generally be detected in urine up to two days after use, while
marijuana may linger for more than a month. See, e.g., Hawks & Chiang, Examples
of Specific Drug Assays, in URINE TESTING FOR DRUGS OF ABUSE 84, 86, 93 (1986).
17. Cross reaction occurs when a substance in the urine that is not a drug
metabolite tests as if it were a misused drug. K. ZEESE, supra note 7, at § 3.01[2][b].
See also Critical Issues in Urinalysis of Abused Substances: Report of the SubstanceAbuse Testing Committee, 34 CLINICAL CHEMISTRY 605, 618 (1988) [hereinafter Issues)
(phenobarbital prescribed for epileptic seizures will show up as barbituate metabolite
up to 38 days after use); id. at 625 (codeine found in cough and cold medicines had
same metabolite as heroin); Guerrero, The FederalRole: Uncle Sam or Big Brother?,
in DRUG TESTING: PROTECTION FOR SOCIETY OR A VIOLATION OF CIVIL RIGHTS? 21, 23

(1987) (Advil, Nuprin, Contac, Sudafed, commercially available diet pills, certain
herbal teas, and poppy seeds all may provide false positive results); Morgan, Urine
Testing for Abused Drugs: Technology and Problems, in DRUG TESTING: PROTECTION
FOR SOCIETY OR A VIOLATION OF CIVIL RIGHTS? 34, 35 (1987) (Consuming two poppy
seed buns will generally cause a person to drug test positive for morphine, as
morphine and poppy seeds produce the same metabolite.).
18. See Issues, supra note 17, at 610. ("[A urine test result] cannot support
any interpretation as to the amount of drug taken, the time it was taken, or the
absence or presence of impairment.").
19. A background medical check would still not determine either the date
ingested or impairment level. However, a screening test such as an EMIT, confirmed
positive by a wholly different and accurate procedure such as GC/MS, and followed
by a background medical check to ensure the "drug" being found in the urine is not
a prescription or cross reaction, would at least establish some level of drug use at a
recent time. See Hawks, Analytical Methodology, in URINE TESTING FOR DRUGS OF
ABUSE 30, 36 (1986). For a discussion of the drug testing procedures mentioned
above, see infra notes 27-63 and accompanying text.

1991:3191

DRUG TESTING

after an initial low-cost "screening" test indicates a positive result, a
more expensive and highly accurate confirmation test is performed
using a different scientific process to discern exactly which metabolite
is present and in what quantity. 20 This secondary procedure is required
under mandatory guidelines for federal employer drug testing, which
are discussed below, 21 although many private employers do not perform any confirmation testing. 22 An interview with the test subject
and a review of the subject's medical records by a competent physician
would eliminate the possibility of an erroneous positive result caused
by cross reactions or normal medication. 23 While the federal guidelines
mandate this interview procedure for governmental testing, interviews
24
are seldom given by non-governmental entities. The private employer
simply has very little incentive under the present status of the law to
ensure highly accurate results when implementing urinalysis drug
testing. 25 These private employers may base employment decisions
entirely upon unconfirmed, inconclusive screening tests with no fur26
ther inquiry as to why the test was positive. With the wide array of
testing procedures and varying degrees of accuracy, an understanding
of these procedures is necessary before conclusions may be drawn
from test results.
1. Common Urinalysis Tests
Of the numerous possible ways to test for drugs in body fluids,
there are basically two testing methodologies that have come into
See Hawks, supra note 19, at 36-38.
See infra notes 75297 and accompanying text.
U.S. General Accounting Office, 1988; Thomas-Holladay et al., 1989.
McMillan, Urine Screening: What Does it Mean?, in PRO.BLEMS OF DRUG
DEPENDENCE 1989 207 (1990)) ("Failure on the part of a company to [confirm]
probably results from ignorance on the part of management as to the importance of
[confirmation] and a desire to do drug testing at the lowest possible cost.").
23. Such an interview would ascertain what other medications or foods the test
subject is ingesting that could cause a cross-reaction. Disclosure of this type of
information could be mandated before the urinalysis, if a concern exists of fabrication, although a medically trained person would know what particular substances
will react in a given way. Employees are assured that personal information will not
unnecessarily be divulged with a post test interview when a positive result is obtained
under the federal guidelines. See Mandatory Guidelines for Federal Workplace Drug
Testing Programs § 2.7, 53 Fed. Reg. 11,970, 11,985 (1988).
24. Id. (requiring interview). See Thomas-Holladay, supra note 22 (private
employers not confirming).
25. See Note, Survey of the Law on Employee Drug Testing, 42 U. ML4MI L.
REv. 553, 659 (1987) ("[At will employees generally] have no recourse to challenge
the results."). But see id. at 660-79 (discussing possible exceptions to general rule).

20.
21.
22.
(cited in

26. Id.
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common usage: the immunoassay and chromatography processes of
urinalysis testing.2 7 Several variations and combinations of these two

processes can be employed, and this comment discusses the five most

popular variations. While other methods exist, most are either not
suitable for large-scale use in an employment setting, or are so grossly
inaccurate as to preclude acceptance even by nonregulated private

employers.2 8 George D. Lundberg, editor of the Journalof the Amer-

ican Medical Association, has commented that urinalysis tests should

be good, fast, and cheap, but that at present no program can combine
these factors.29 The tests that best approach these goals are described

below.
a.

Immunoassay

Immunoassay tests are the most widely used screening tests, as
they are quick and inexpensive. 0 The three most prevalent immuno-

assay tests are enzyme immunoassay, radioimmunoassay, and fluorescein polarization immunoassay. They are based on the principle that
known "labels"'" and the unknown drug metabolites present in the
urine will compete to bind to an antibody. First the "label" and
antibody are combined, forming a chemical bond. When the urine is
added, drug metabolites present in the urine will displace the "label"
and bond in its place to the antibody. By measuring the unbound
"label" with ordinary laboratory methods, the amount of drug me-

tabolite originally present in the urine can be determined.3 2

The simplest and least expensive test available is the enzyme
immunoassay (EIA), making it the most commonly used test.33 The
most prevalent EIA in the United States is the EMIT test produced
by Syva Company which costs about $4.50 per use.3 4 EIA tests are
27. See generally K. ZEESE, supra note 7, at § 2.02.
28. See supra note 8 and accompanying text.
29. Holden, Doctors Square Off on Employee Drug Testing, 238 Sci. 744, 744
(Nov. 6, 1987).
30. K. ZEESE, supra note 7, at § 2.02[l].
31. The "label" is also frequently called the indicator, as it is measured to
indicate the amount of drug metabolite present. The main difference between various
types of immunoassay is in the indicator/label used. See Hawks, supra note 19, at
30; K. ZEESE, supra note 7, at § 2.02[1]; Comment, supra note 5, at 1014-15.
32. See id.
33. K. ZEESE, supra note 7, at § 2.02[l].
34. See Hawks, supra note 19, at 30 (most prevalent); Comment, Use and

Abuse of Urinalysis Testing in the Workplace: A Proposalfor Federal Legislation
Limiting Drug Screening, 35 EMORY L.J. 1011, 1013 n.7 (citing M. ROTHSTEIN,
MEDICAL SCREENING OF WORKERS 35 (1984)) (EIA cost of $4.50).
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extremely sensitive (they can detect very low levels of drug metabolite),
however they tend to "cross-react" 35 and are not specific as to the
exact type of metabolite present.3 6 EIA tests are generally marketed
as "screening" tests for use in culling out large numbers of test
subjects, with those testing "positive" being confirmed using a more
metabolite specific test such as gas chromatography/mass spectromeof being easily autotry (GC/MS).17 EIA has the added advantage
38
mated to handle large quantities of samples.
Radioimmunoassay (RIA) is a similar test to the EIA, but with
a more sensitive indicator. 39 RIA can detect lower levels of drug
metabolite present in the urine, but also has problems with cross
reactions.4 While still a comparatively simple process, it is not a
homogenous test like the EIA; RIA requires an additional step to
4
separate the free and bound indicator prior to measurement. ' RIA
also uses a radioactive indicator which causes handling and disposal

problems

42

Fluorescein polarization immunoassay (FPIA) does not require
43
separation like RIA, and is easily measured by fluorescence. Like
other immunoassays, FPIA is based on competition between a known
"label" and the unknown drug metabolite in binding to an antibody."
The unbound label is then measured by fluorescence, with lower light
45
emission corresponding to higher drug metabolite quantities. Although FPIA is a newer technique, it uses common, established
laboratory procedures for the measurements." The immunoassays are
all fairly inexpensive, but not as accurate as chromotography methods.
35. For an explanation of cross reaction, see supra note 17 and accompanying
testing is especially vulnerable to cross reactions. K. ZEESE, supra
Immunoassay
text.
note 7,at § 3.0112][b].
36. See generally K. ZEESE, supra note 7, at § 3.01[2][b].
37. This is due to the relatively low cost of EIA testing (about $4.50 per use)
compared to GC/MS testing, which may approach $100 per test. The lower cost EIA
test is used to save money in eliminating suspicion of the majority of test subjects,
but because of cross-reaction problems, "[EIA tests] must be confirmed by a second
and distinctly different analytical technique." Hawks, supra note 19, at 36. See
generally K. ZEESE, supra note 7, at § 2.02[1].
38. See Hawks, supra note 19, at 31; Issues, supra note 17, at 611.
39. See Hawks, supra note 19, at 31.
40. See K. ZEESE, supra note 7, at § 3.01[21[b].
41. See Issues, supra note 17, at 611.
42. See Hawks, supra note 19, at 31.
43. K. ZEESE, supra note 7, at § 2.02[l][c].

44. Id. See generally supra note 31 and accompanying text.
45. K. ZEESE, supra note 7, at § 2.0211][c].
46. Id.
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Chromatography

Chromatography methods are more accurate than immunoassay
methods, but are also more complicated and expensive. In chromatography, the specimen is separated into various components, which
are then identified and measured.47 Chromatography requires a stationary (fixed) phase which may be a solid or liquid, and a mobile
(moving) phase which may be a liquid or gas.48 Substances from the
urine sample are carried by the mobile phase across the stationary
phase by capillary action, and the stationary phase interacts with these
substances to separate them. 49 After separation, a detection method
distinguishes the components for identification and measurement.5 0
One of the oldest methods of chromatography, thin-layer chromatography (TLC) is still commonly used. 5 In TLC, the extracted
urine sample is combined with just enough solvent (mobile phase) to
wet the bottom of an absorbent (stationary phase). 2 The solvent will
carry the urine sample across the absorbent through capillary action,
allowing the substances to separate. 3 The separated substances are
then identified by spraying the absorbent with reagents that produce
various color reactions.5 4 Drug metabolites are then identified by the
(1) distance the substance is carried by the solvent across the absorbent, (2) movement patterns, and (3) color reaction." While TLC can
be very accurate, it has several disadvantages. Reliability is highly
dependent on the skill and experience of the analyst and interpretation
is subjectively based on the analyst's color perception and pattern
6
recognition.1
Gas chromatography/mass spectrometry (GC/MS) is the "technique of choice" for identifying drug metabolites in urine.5 7 This
combines the separating power of gas chromatography with the "high
sensitivity and specificity of mass spectrometric detection." 58 The first
step of this process requires a gaseous mobile phase with ordinary
47.
48.
49.
50.
51.
52.
53.
54.
55.

See Hawks, supra note 19, at 32.
Id.
Id.

Id.
Id.

Id.at 33.
Id.
Id.
Id.

56. See Issues, supra note 17, at 621; Hawks, supra note 19, at 32-33.
57. Issues, supra note 17, at 612.
58. Hawks, supra note 19, at 35.
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chromatography. 9 The detection phase next used to identify the
separated drug metabolites utilizes a highly accurate mass spectrometry process. 60 This mass spectrometry can detect a "fingerprint"

pattern that is unique for each drug, and can be extremely accurate
if there is a sufficiently high6 concentration of the drug to provide a
good quality mass spectrum. '

However, due to the complicated process and high cost, this is
generally used only to confirm positive tests from a less accurate
method. 62 This process also depends highly on the analyst's skill, but
in a competent lab the results are almost conclusive. 63 The federal
guidelines, discussed below, require this test to confirm any positive
4
screening result when used in relation to the Federal government.
B.

FEDERAL GUIDELINES

During the last decade the drug problem has received greatly
65
increased publicity from both the media and the government. In
1984, the House Select Committee on Narcotics and Drug Abuse and
Control estimated that drug trafficking had become a $110 billion per
year business in the United States. 66 The National Institute on Drug
Abuse has reported that twenty million Americans use marijuana and

59. See supra notes 48-56 and accompanying text for a description of the
chromatography process. The first step of GC/MS follows this process, although the
substances are detected with a much more accurate method in GC/MS.
60. See Hawks, supra note 19, at 35. Mass spectrometry determines the precise
mass of ions by measuring separation and charge by the action of electric and
magnetic fields. See THE ENCYCLOPEDIA OF CHEMISTRY 661 (3d ed. 1988).
61. Id.
62. Id. at 35-36.

63. Id. at 35. But cf.

NATIONAL INSTITUTE ON DRUG ABUSE

(NIDA), RESEARCH

GC/MS ASSAYS FOR ABUSED DRUGS I BODY FLUIms 22-23 (1980)
(mentioning rare cases where ions interfere: "When this situation occurs it can easily
go undetected and result in erroneous data.").
64. See Mandatory Guidelines for Federal Workplace Drug Testing Programs
§ 2.4(f), 53 Fed. Reg. 11,970, 11,983 (1988) [hereinafter NIDA Guidelines].
65. See, e.g., Wisotsky, Crackdown: The Emerging "Drug Exception" to the
Bill of Rights, 38 HASTINGS L.J. 889, 891 (1987) (arguing that government has
exaggerated and over-publicized the drug problem); Comment, supra note 3, at 561
(media may be collectively inflating problem).
66. See Comment, Survey of the Law on Employee Drug Testing, 42 U. MIAMI
L. REV. 553, 557 (1988) (citing House Select Comm. on Narcotics and Drug Abuse
and Control, Annual Report for the Year 1984, H.R. REP. No. 1199, 98th Cong.,
2d Sess. 9 (1985)).
MONOGRAPH #32
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four million Americans use cocaine. 67 While difficulties arise in trying

to estimate the effect this drug use has had on America's work force,

illicit drug use costs industry approximately twenty-six billion dollars
annually. 6s This drug use also resulted in thirty-seven fatalities and

eighty injuries between 1975 and 1984 in the Federal Railroad system
69
alone.

1. Drug-FreeFederal Workplace: Executive Order 12564 of 1986
In response to these staggering figures on American drug use,
President Ronald Reagan issued an executive order calling for a
"drug-free federal workplace" on September 15, 1986.70 This order

required the head of each Executive agency to develop a drug testing
program, to specifically include "employees in sensitive positions. ' ' 7
The Order also authorized the Secretary of Health and Human

Services to promulgate scientific and technical guidelines for drug
testing programs, and required agencies to follow these guidelines
once promulgated.7 2 While this order did not directly apply to private
companies, it affected civil service employees and created the NIDA
Guidelines for drug testing programs. 73 These NIDA Guidelines are

67. Id. at 557 (citing OSHA Oversight Hearing on the Impact of Alcohol and
Drug Abuse on Worker Health and Safety: Hearings of the House Subcomm. on
Health and Safety of the Comm. on Education and Labor, 99th Cong., 1st Sess. 5
(1985)).
68. Id.
69. Id. at 559.

70. Exec. Order No. 12,564, 3 C.F.R. 224, 226 (1987) reprinted in 5 U.S.C. §
7301 (Supp. V 1987).
71. The Order defines "employee in a sensitive position" to include: employees
with special sensitive designations in the Federal Personnel Manual, employees who
may be granted access to classified information, individuals serving under Presidential
appointments, law enforcement officers, and others. Executive Order No. 12,564, 51
Fed. Reg. 32,889, 32,892-93 (1986).
72. See Exec. Order No. 12,564, supra note 70, at § 4(d). See generally NIDA

Guidelines, supra note 64 (promulgated by Department of Health and Human Services
specifically in response to this order); Sullivan, Federal Agencies Plan for Drug
Testing, in 4 NIDA NOTES 12 (1988/89).
73. Congress also enacted the Drug-Free Workplace Act of 1988. Pub. L. No.
100-690, Title V, Subpart D, 102 Stat. 4304 (1988), (codified as amended at 41
U.S.C. §§ 701-702 (1990). This act applies to any recipient of a government contract
in excess of $25,000, and requires participants to certify that they will maintain a
drug-free workplace. The act does not specifically have a provision for drug testing
and is therefore not covered in this comment. Id. See generally PRACTISING LAW
INSTITUTE, TRENDs IN THE LAW 1988-89 3 n. 13 (1989). The NIDA guidelines themselves are not mandated for government contractors. See infra note 74 and accompanying text.
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mandatory for any federal employer except the postal service, judiciary, and certain legislative branch employers. 74
2. Mandatory Guidelinesfor Federal Workplace Drug Testing
Programs
75
Pursuant to the Drug-Free Federal Workplace executive order,
the National Institute on Drug Abuse agency of the Department of
Health and Human Services [hereinafter NIDA] developed a set of
stringent guidelines for Federal workplace drug testing.76 These NIDA
Guidelines specifically spell out various procedures and qualifications77
a laboratory must meet to become certified to do federal testing.
The NIDA guidelines also cover the collection and custody of the
samples from initial collection through the testing and 78mandatory
storage period to allow further testing if a dispute arises.
Under NIDA guidelines, collection of urine specimens is prescribed in detail, with an unobserved collection allowed. 79 However,
the collection process is strictly controlled. Procedures call for toilet
bluing agents to prevent adulteration of the collected sample with
water. The collection stall area must also have no sink or fountain,
and outer garments, jackets, purses, and briefcases are not allowed
into the collection stall. The person giving the specimen must also
wash his or her hands first to reduce the possibility of concealing
contaminants under the fingernails, and the temperature of the sample
to ensure that it
must be measured within four minutes of collection
80
stall.
the
into
carried
not
and
voided
freshly
was
Strict procedures also govern the "chain of custody, ' ' 81 and the
laboratory. Security is very stringent, with the lab kept locked at all
74. See NIDA Guidelines, supra note 64, at § 1.1.
75. Exec. Order No. 12,564, supra note 70.
76. NIDA Guidelines, supra note 64.

77. See id.

78. See id. See generally Porro, Courts Settle Difficult Questions Regarding
Workplace Drug Testing, OCCUPATIONAL HEALTH & SAFETY 48 (Nov. 1989).
79. NIDA Guidelines, supra note 64, at § 2.2.

80. See id.

81. Chain of custody refers to the procedure where every person handling the
specimen is accounted for on a form attached to the specimen. The purpose of
maintaining a chain of custody procedure is to ensure that any urine being tested
was definitely provided by the test subject who will suffer the consequences of for
Executives, in

DRUG TESTING: PROTECTION FOR SOCIETY OR A VIOLATION OF CIVIL

27, 27 (1987). The NIDA Guidelines require a minimum of a form showing
"entry documenting date and purpose each time a specimen or aliquot is handled or
transferred and identifying every individual in the chain of custody." NIDA Guidelines, supra note 64, at § 1.2.
RIGHTS?
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times. Anyone entering or leaving the lab must have documented
authorization, and visitors must be escorted.8 2
Initial drug screening must be by approved immunoassay procedure, and any positive results must be confirmed by gas chromatography/mass spectrometry, with threshold levels for each drug
specified.83 The threshold level is the defined metabolite concentration
that must be detected in the urine sample before a test is considered
"positive". 84 Threshold levels must be carefully selected to be low
enough to detect actual drug use but high enough to ensure accurate
results.85 The Guidelines also call for each agency to employ a
"Medical Review Officer" who interviews any test subject receiving
a confirmed positive result.8 6 The function of this Medical Review
Officer is to ensure that the positive result is not the consequence of
a cross reaction or normal prescription drug use before any disciplinary action is taken against the employee.
The NIDA Guidelines also specify the credentials required for
the lab supervisory personnel and describe what records must be
kept.8 7 In addition to initial lab certification, NIDA sends bi-monthly
test specimens to be analyzed by each lab.88 The labs must be able to
measure concentrations of drug metabolites in the specimen with a
high degree of accuracy, and any "false-positive" 8 9 result may suspend
certification.9
Although the NIDA guidelines do not apply to private companies, 9' recently the Department of Transportation has required private
companies regulated by them to use NIDA-accredited labs.9 2 This will
mandate compliance in the airline, maritime, mass transit, railroad,
82. NIDA Guidelines, supra note 64, at § 2.4.
83. NIDA Guidelines, supra note 64, at § 2.4(e).
84. Black, Testing for Abused Drugs: A Primer for Executives, in DRUG

TESTING: PROTECTION FOR SOCIETY OR

A

VIOLATION OF CIvIL RIGHTS? 26, 27 (1987).

85. See generally id. at 30-31.
86. NIDA Guidelines, supra note 64, at § 2.7. This medical review officer must
be a "licensed physician with knowledge of substance abuse disorders." Id.
87. See id. at § 2.3 (required personnel credentials); id. at § 2.4(m) (documen-

tation required).
88. Id. at § 3.17.
89. Id. A "false-positive" is any test result indicating presence of a drug
metabolite where in fact there is not any metabolite. This is normally considered
more serious than a "false-negative," where a test fails to indicate drugs that are in
fact present, because the error can have devastating consequences to the employee.
See Black, supra note 84, at 31.
90. NIDA Guidelines, supra note 64, at § 2.5(6).

91. Id. at § 1.1.
92. Porro, supra note 78, at 48.
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pipeline, and trucking industries. 9 Bills have also been proposed in

both the 100th and 101st Congress for private labs to adopt the NIDA
standards, but as yet no law has been passed. 94
Although NIDA has attempted to establish a voluntary qualitycontrol program for private labs, 95 these companies are driven by the
"marketplace, not the scientific community." 9 At present, private

employers have no regulations affecting their implementation of drug
testing programs and remain essentially free to do as they please
97
under the employee-at-will doctrine.
C.

PRIVATE EMPLOYERS AND THE "EMPLOYEE-AT-WILL" DOCTRINE

Employees may be classified into three groups for purposes of
drug testing: private "at-will" employees,98 public sector employees,99
and organized labor.1° Because the latter two groups generally have
constitutions, unions, and grievance procedures to protect them from
potential abuses of urinalysis testing,' 0 this comment concentrates on
93.
94.
(1989).
95.
20, 1986,

Id.
H.R. 2951, 100th Cong., 1st Sess. (1989); H.R. 33, 101st Cong., 1st Sess.
Budiansky, Busting the Drug Testers, U.S.
at 70.

NEWS & WORLD REPORT, Oct.

96. Glasser, Why Indiscriminate Urine Testing is a Bad Idea, in DRUG TESTING:

PROTECTION FOR SOCIETY OR A VIOLATION OF CwVI

RIGHTS? 77, 78 (1987).

97. This "at-will" doctrine is based upon the theory that a private employee
negotiates for an occupation and is free to accept the employer's terms of employment
or work elsewhere. There are few restrictions on the employer's discretion, as the
employees are not compelled to accept employment if the employer places unreasonable demands on them. A detailed explanation of the at-will doctrine is beyond the
scope of this article. See F.

PERRITT, EMPLOYEE DIsMIsSAL LAW AND PRACTICE §§

1.1-1.17 (2d ed. 1987).
98. At-will employees would include any employees not specifically covered by
a contract for a fixed duration, or otherwise fitting into the two latter groups
discussed below. See generally Id. at §§ 1.1-1.17.
99. A public sector employee includes any government employee or any private
employee whose employer has a "nexus" to the government or is sufficiently under
government control to be legally treated as a government employer. See, e.g., Blum
v. Yaretsky, 457 U.S. 991, 1004 (1982) (constitutional constraints apply to private
entities if sufficient governmental nexus).
100. The legislation this note proposes would apply to organized labor as well,
but the need for regulation is not as strong in this area because employees are better
represented and can bargain for drug testing standards. For purposes of this comment,
contract employees and organized labor groups are considered to be similarly situated

as both their employers have less discretion than in the employee-at-will case.

101. The fourth amendment does not govern private action and unionized
employees generally have enough bargaining power to negotiate the terms of drug
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the "at-will" employee in the context of employment urinalysis testing.
Private employers generally have more latitude in implementing
drug testing programs than government employers, as a private employer in most states is not bound by constitutional constraints or the
previously mentioned NIDA Guidelines. 0 2 The only possible restraints
on a private at will employer would be lawsuits brought under state
common law, with little chance of success. 03 Under the employment
at will doctrine, private employers "may dismiss their employees atwill ... for good cause, for no cause or even for cause morally
wrong." °0Under this rationale, a disgruntled employee has absolutely
no standing to challenge drug testing procedures or resulting discharges. 0 5 While most jurisdictions have somewhat relaxed the common law rule, 0 even the most liberal jurisdictions still leave the
employer's discretion virtually unfettered when implementing a drug
07
testing program.

testing programs. See, e.g., Lovvorn v. City of Chattanooga, 846 F.2d 1539, 1560
(6th Cir. 1988) (Guy, J., dissenting) (stating established law that "[p]rivate employers
who want to institute a drug testing program may do so and need not concern
themselves with the fourth amendment").

102. Note, Employee Drug Testing-Issues Facing Private Sector Employers, 65

N.C.L.

REV.

832, 833 (1987). Constitutions do not limit private employers as state

action is required before constitutional protections can be invoked. See Blum v.
Yaretsky, 457 U.S. 991, 1004 (1982).
103. F. PERRITT, EMPLOYEE DISMISSAL LAW AND PRACTICE §§ 1.1-1.17 (2d ed.
1987).
104. Payne v. The Western & Atlantic R.R., 81 Tenn. 507, 519-20 (1884),
overruled on other grounds, Hutton v. Watters, 132 Tenn. 527, 179 S.W. 134 (1915).
105. The "at-will" doctrine operates on the premise that the employee has totally

free will to accept or reject the terms of employment. An employee disgruntled over

a drug testing program may seek work elsewhere, but would have no legal theory to
challenge the employer's actions. See, e.g., Note, Employment at Will in IllinoisHas the Employer Been Forgotten?, 9 N. ILL. U. L. REV. 603, 606 (1989).
106. Ross, Trends in the Law 1988-1989, in 18TH ANNUAL INSTITUTE ON EMPLOYMENT LAW 9.24 (1989) ("at least 40 jurisdictions have blunted or relaxed the
common law rule . . ").
107. The majority of employees are "at-will" employees which gives their
employers wide discretion in implementing drug testing programs. See generally
McGovern, Employee Drug-Testing Legislation:Redrawing the Battlelinesin the War
on Drugs, 39 STAN. L. REV. 1453 (1987) (discussing the at-will doctrine and showing
what regulations apply in each state). Colorado, Delaware, Florida, Georgia, Iowa,
Louisiana, Mississippi, Rhode Island, Utah, and Vermont completely retain the "atwill" doctrine. K. ZEESE, supra note 7, at § 4.01[1].

1991:3191

DRUG TESTING

III.

PRESENT STATUS OF THE LAW

The courts are still establishing the common law affecting drug
testing, with very little precedent to guide their decisions. Most
available case law has been addressed to public sector employment,
where the constitutionality of search and seizure of urine has been
the focus. 08 There have not been any private "at-will" employer drug
testing cases to reach the Supreme Court yet, although narrow holdings have been reached concerning public employees'0 9 and private
employers with a government "nexus" who are treated as government
employers for application of constitutional principles"0 . Some insight
to private at will employers' drug testing may be gained from the
Supreme Court's holdings in these cases, even though they do not
directly deal with private employers.
The recurring issues in drug testing cases are: privacy interests of
employees forced to urinate in an observed or semi-observed situation,
testing method accuracy, urine handling integrity both at collection
time and throughout the lab analysis, laboratory safeguards and
procedures, and use and dissemination of test results."' Courts generally group these interests together under the headings of privacy
and test accuracy, but it should be remembered that accuracy in this
broad sense is highly dependent upon collection," 2 test methods,"'
and laboratory techniques."1 4 An examination of the present case law
shows that courts generally do not distinguish and consider each of
the factors related to accuracy.
108. See, e.g., National Treasury Employees Union v. Von Raab, 489 U.S. 656
(1989); Skinner v. Railway Labor Executives' Ass'n, 489 U.S. 602 (1989). See generally
K. ZEESE, supra note 7, at § 5 (general discussion of several lower court decisions
regarding public employment drug testing).
109. National Treasury Employees Union v. Von Raab, 489 U.S. 656 (1989).
110. Skinner v. Railway Labor Executives' Ass'n, 489 U.S. 602 (1989).
111. See, e.g., K. ZEESE, supra note 7, at § 4 (outlining issues and possible
causes of action for private at-will employee).
112. The major concern with collection is in proper labeling and handling of
the urine specimen to ensure that the test results are in fact a product of the test
subject's urine and not that of a co-worker.
113. See supra notes 27-61 and accompanying text for a discussion of urinalysis
testing.
114. Laboratory techniques and procedures are especially difficult for the lay
person to evaluate, and this is a major factor in accuracy. With the recent upsurge
in drug testing, many new labs have opened with varying degrees of quality. See

Hansen, Caudill & Boone, Crisis in Drug Testing: Results of CDC Blind Study 253

J. A.M.A. 2382, 2383 (1985) (study found false positive error rates in a blind
proficiency testing program ranged from zero to one hundred percent).
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SUPREME COURT CASES

The Supreme Court decided two drug testing cases in 1989,
Skinner v. Railway Labor Executives' Assn." 5 and National Treasury
Employees Union v. Von Raab." 6 Although neither of these cases
was decided in the private employer context, they do indicate values
that the Court places on employee privacy and drug testing accuracy.
Skinner reversed a previously successful challenge to mandatory
blood and urine testing of railroad employees involved in accidents
or incidents." 7 The regulation upheld in Skinner also authorized, but
did not mandate, breath or urine testing for railroad employees
violating certain safety rules."'8
The Skinner Court first took notice of the pervasive history of
drug and alcohol abuse in the railroad industry."19 Then the Court
acknowledged that urinalysis constitutes a "search" for Fourth
Amendment purposes, quoting the fifth circuit opinion:
There are few activities in our society more personal or private
than the passing of urine. Most people describe it by euphemisms if they talk about it at all. It is a function traditionally
performed without public observation; indeed, its performance
in public is generally prohibited by law as well as social
custom. 20
After making this strong statement in determining that a search
had occurred, the Skinner Court next examined the employees' privacy
interests, which were characterized as minimal in the context of a
diminished expectation of privacy in a highly regulated industry such
as the railroad situation.' 2 ' These "minimal" privacy interests were
finally balanced against the government's "compelling" interest in
preventing accidents, and of course the testing regulations were upheld.'22
On the same day Skinner was decided, the Court also upheld
drug testing of National Treasury Employees under NIDA Guidelines

115. 489 U.S. 602 (1989).
116. 489 U.S. 656 (1989).
117. Skinner v. Railway Labor Executives' Ass'n, 489 U.S. 602 (1989).
118. Id. at 611.
119. Id. at 608.
120. National Treasury Employees Union v. Von Raab, 816 F.2d 170, 175 (5th
Cir. 1987), rev'd, 489 U.S. 656 (1989).
121. Skinner v. Railway Labor Executives' Ass'n, 489 U.S. 602, 627 (1989).
122. Skinner, 489 U.S. at 628, 634.
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in National Treasury Employees Union v. Von Raab 2 3 Von Raab
had additional safeguards on employee privacy because test results
could not be turned over to law enforcement agencies, and disclosure

of employee medical information was not mandated until after a
failed test. 24 However, the Von Raab case did not involve a showing
of a pervasive drug problem; in fact, the Commissioner of Customs
himself had stated that "Customs is largely drug-free.'

'1 25

The Court

instead relied on a blanket statement that drug abuse is one of the
most serious problems in today's society, and assumed the workplace
has a pervasive problem. 26 The Von Raab Court seemed to rely
heavily on the NIDA Guidelines circumscribing the employer's discre-

tion,

27

governmental interest outand once again the compelling
2

weighed the employees' privacy.

1

In both of these Supreme Court cases, urinalysis drug testing was
performed in accordance with the NIDA guidelines'29 which the court
characterized as "highly accurate."' 310 The Court also showed strong
support for counteracting the drug problem: "nor can there be doubt,

that drug abuse is one of the most serious problems confronting our
society today."'' When this strong concern for the drug problem is
taken together with the Court's characterization of the test subject's
privacy interests'3 2 implicated by a urinalysis as "minimal" in Skin-

123. 489 U.S. 656 (1989).
124. National Treasury Employees Union v. Von Raab, 489 U.S. 656, 673 n.2
(1989). The NIDA Guidelines mandate disclosure only after a failed drug test to
protect against needless dissemination of highly private information. See NIDA
Guidelines, supra note 64, at §§ 2.7(c)-2.8.
125. Von Raab, 489 U.S. at 683 (Scalia, J., dissenting).
126. Von Raab, 489 U.S. at 674.
127. Von Raab, 489 U.S. at 667 (because all procedures are carefully mandated,
"no special facts for a neutral magistrate to evaluate") (quoting South Dakota v.
Opperman, 428 U.S. 364, 383 (1976) (Powell, J. dissenting)).
128. Von Raab, 489 U.S. at 668.
129. These guidelines call for a screening test by immunoassay procedure, with
any positive results to be confirmed by gas chromatography/mass spectrometry. See
NIDA Guidelines, supra note 64, at § 2.4.
130. National Treasury Employees Union v. Von Raab, 489 U.S. 656, 672
(1989).
131. Id. at 674.
132. The Court placed emphasis that NIDA standards did not require a directly
observed urination, although the NIDA guidelines do call for an observed urination
if the test proctor's suspicion is aroused by odd sounds or behavior of the test
subject. NIDA Guidelines, supra note 64, at § 2.2(16). The Court also stressed that
in this case, the sample was collected in a "medical environment, by personnel
unrelated to the railroad employer," a situation not required of private employers.
See Skinner v. Railway Labor Executives' Ass'n, 489 U.S. 602, 626-27 (1989).
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ner,'3 a private employee trying to bring suit in relation to an
employment drug test should not expect to find a very enthusiastic
bench. 3 4 These Supreme Court cases have not given much guidance

to the lower courts in addressing private at-will employer drug testing
concerns.
B. LOWER COURTS

Decisions in the federal appellate courts, state courts, and labor
arbitration courts vary considerably in their holdings,'35 in part because the Supreme Court has never addressed private at-will employer

drug testing. Several lower courts that were willing to strike down the
validity of urinalysis did so on the basis of the tests infringing on the

316
privacy of the employee by revealing off-work activity to the employer
and not necessarily measuring current impairment.' 37 This privacy
concern is no longer as strong in light of the Supreme Court's recent
decisions. In Von Raab the Court stated that the government may
have a compelling interest in ensuring that employees do not use
drugs even off-duty, 3 ' and in Skinner the Court noted that the test is
not required to conclusively establish impairment in order to be
relevant. 3 9 The Supreme Court has struck the balance between employee privacy and the employers' interest in discovering drug activity

133. Id. at 624.
134. Skinner was decided in the public employer context, with constitutionally
mandated privacy interests. A private employer would have much greater latitude
because the fourth amendment is not implicated. See supra note 101 and accompanying text.
135. Compare Harmon v. Auger, 768 F.2d 270 (8th Cir. 1985) (EMIT test held
to be "sufficient" to justify its use for prisoner testing) with Jones v. McKenzie, 628
F. Supp. 1500, 1506 (D.D.C. 1986) (dismissing a school bus driver based upon a
single unconfirmed EMIT test was arbitrary and capricious), rev'd in part, vacated
in part, 833 F.2d 335 (1987) (single issue on appeal was drug testing without probable
cause), vacated, 490 U.S. 1001 (1989). Compare also Luedtke v. Nabors Alaska
Drilling, 768 P.2d 1123 (Alaska 1989) (allowing employer to fire based upon drug
test taken during employee's 30 day vacation, without employee's knowledge that
urine would be tested for drugs) with Luck v. Southern Pac. Transp. Co., 218 Cal.
App. 3d. 1, 267 Cal. Rptr. 618 (1990) (affirmed award of $485,000 to computer
programmer after employer fired her for refusal to submit to urinalysis drug test).
136. See Critical Issues in Urinalysis of Abused Substances: Report of the
Substance-Abuse Testing Committee, supra note 17, at 621 (positive results may
linger in urine over one month after drug intake).
137. See supra note 18 and accompanying text. See, e.g., Movielab, 50 Lab.
Arb. (BNA) 632, 633 (1969).
138. 489 U.S. 656, 674 (1989).
139. 489 U.S. 602, 631-32 (1989).
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much closer to the employers' side than these lower courts had done.
Based upon this rationale, it would appear that employers would have
no legal impediment (at least on the federal level) in using urinalysis
drug testing even where the tests may report off duty activity and not
on-the-job impairment.
Lower courts are left with relatively little direct guidance when
deciding drug testing cases in the private employment context, which
accounts for their inconsistent, varying opinions.'14 An extreme example of this inconsistency is shown in the 1989 Alaska Supreme
Court opinion of Luedtke v. Nabors Alaska Drilling.'4' The Luedtke
decision was a consolidation of two claims, but Paul Luedtke had the
most egregious claim, and this note will restrict discussion to his case.
Paul Luedtke was an employee who worked on a remote oil
drilling rig located on the North Slope of Alaska.' 42 Luedtke scheduled
a two-week vacation, and since his normal work schedule was two
weeks of work on the North Slope, followed by a week off, this
vacation amounted to 28 consecutive days away from work.' 43 Luedtke
was instructed to arrange for a physical examination during his
vacation, but he was not informed that this would included a urinalysis
drug test and his employer had not previously administered drug
testing. 144
Luedtke voluntarily produced a urine sample in conjunction with
his physical examination, but assumed it would be tested only for
"blood sugar, any kind of kidney failure [and] problems with bleeding.' ' 45 Nabors' announced their policy of testing for drug use 13
days after Luedtke's examination, and suspended Luedtke for "the
use of alcohol or other illicit substances."' 46 Luedtke was later fired
when he refused to submit to two subsequent tests which he was
required to pass as a condition of returning to work.' 47 Luedtke sued
Nabors for wrongful dismissal and breach of contract.
The Luedtke court first examined the right to privacy, which has
foundation in the Alaska state constitution extending beyond the
federal Constitution. However, the court48 declined to extend this
constitutional protection to private action.'
140. See supra note 108 and accompanying text.
141. 768 P.2d 1123 (Alaska 1989).
142. Luedtke v. Nabors Alaska Drilling, 768 P.2d 1123, 1125 (Alaska 1989).
143. Id.

144.
145.
146.
147.
148.

Id.
Id.
Id.at 1126.
Luedtke v. Nabors Alaska Drilling, 768 P.2d 1123, 1126 (Alaska 1989).
Id. at 1130.

NORTHERN ILLINOIS UNIVERSITY LA W REVIEW

[Vol. I11

Next, the Luedtke court weighed the public policy supporting
employee privacy against public policy supporting health and safety.
The court spoke of urine testing as "involving one of the most private
of functions", and called it a "form of surveillance", reporting offduty activities as if "George Orwell's Big Brother Society [had] come
149
to life''.
After making these strong observations about urine testing, the
court noted that there is little difference between the intrusiveness of
urine testing and other affronts to privacy regularly accepted by
50 The court then switched the
society. 1
issue from the conduct of urine
tests to the reasons behind the testing. 151
Next, the court examined the negative effects of marijuana use
and the extreme importance of maintaining a safe, drug free workplace. The strong public policy supporting the health and safety of
other workers was determined to allow intrusions into employee
privacy if testing was conducted at a time "reasonably contemporaneous with the employee's work time."' 5 2
Finally, the Luedtke court determined that the testing employed
by Nabors was reasonable because the paramount health and safety
concerns justified determining if Luedtke could possibly be impaired
on the job by drug usage off the job.' 53 While not explicitly approving
the testing of Luedtke during his month away from work, the court
held that his discharge was valid based on his refusal to submit to
future tests. The court remanded the case to the trial court for
determination of whether Luedtke's initial suspension may have violated Alaska's implied covenant of good faith and fair dealing in
employment. However, considering the court's ruling and its further
54
approval of a $25,000 award of attorney fees against Luedtke,'
litigation over his work suspension would appear less than prudent.
While cases appear unclear in the area of private employer drug
testing, the existing statutes do not clarify the law. Although a number
of statutes may collaterally apply to private employer drug testing,
149. Id. at 1134 (quoting Capua v. City of Plainfield, 643 F. Supp. 1507, 1511
(D.N.J. 1986)).
150. The court mentioned public rest-rooms and medical record disclosure as
regularly accepted affronts to privacy, and further characterized urine as a "waste
product," which contradicts an objectively reasonable expectation of privacy in urine.
Luedtke v. Nabors Alaska Drilling, 768 P.2d 1123, 1134 (Alaska 1989).
151. Id. at 1135.
152. Id.at 1136.
153. Id.
154. Id.at 1138.
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two of these statutes are frequently analogized to this situation.'"
Various state statutes may also offer protection, but the lack of
uniformity and interpretational problems do not make these statutes
156
a clear solution.
C.

FEDERAL STATUTES

The two statutes most frequently analogized to private employer
drug testing are the Employee Polygraph Protection Act, which
effectively prohibits a private employer from using lie detector tests
in connection with employment, 5 7 and the Vocational Rehabilitation
Act of 1973, which prohibits employers who receive federal funds
from discriminating against handicapped individuals.' 8
At first glance, the rationale for the Polygraph Act would appear
to support similar prohibitions in the drug testing arena. 19 There are
similarities because both drug and polygraph tests use scientific but
inexact technology and may intrude upon employees' off-work privacy. However, the analogy is considerably weakened in light of
exceptions in the Polygraph Act for drug handlers ' 60 and the fact that
Congress passed the Drug-Free Workplace Act of 1988161 during the
same session that it restricted polygraph testing. Given these exemptions and the enactment of the Drug-Free Workplace Act, the Poly155. See Employee Polygraph Protection Act of 1988, Pub. L. No. 100-347, 102
Stat. 646 (1988) (codified as amended at 29 U.S.C. §§ 2001-2007 (1990)); Vocational
Rehabilitation Act of 1973, Pub. L. No. 93-112. 87 Stat. 355 (1973) (codified as
amended at 29 U.S.C.S. §§ 701-796 (Law. Co-op. 1990 & Supp. 1991)).
156. See supra notes 103-107 and accompanying text.
157. Pub. L. 100-347, 102 Stat. 646 (1988) (current version at 29 U.S.C.S. §§
2001-07 (Law. Co-op. 1990)).
158. See Pub. L. No. 93-112, 87 Stat. 355 (1982) (codified as amended at 29
U.S.C.S. §§ 701-796 (Law. Co-op. 1990 & Supp. 1991)).
159. Many commentators have applied the rationale of the Polygraph Act to

drug testing. See, e.g., Glasser, Why Indiscriminate Urine Testing Is a Bad Idea, in
DRUG TESTING: PROTECTION FOR SOCIETY OR A VIOLATION OF Crvn. RIGHTs? 77 (1987);

Imwinkelried, Some Preliminary Thoughts on the Wisdom of Governmental Prohibition or Regulation of Employee Urinalysis Testing, 11 NOVA L.J. 563, 566 (1987);
Note, Protecting Employees and Neglecting Technology Assessment: The Employee
Polygraph Protection Act of 1988, 55 BROOKLYN L. REV. 1315, 1342 (1990); Comment, Employer-Employee Relations-The Employee Polygraph Protection Act:
Eliminating Polygraph Testing in Private Employment Is Not the Answer, 11 S. ILL.
U.L.J. 355 (1987).
160. See 29 U.S.C. §§ 2006(0 (1988) (exemptions for "drug security, drug theft,
or drug diversion investigations").
161. Pub. L. No. 100-690, Title V, Subpart D, 102 Stat. 4304 (1988) (codified
as amended at 41 U.S.C. §§ 701-702 (1990)).
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graph Act's rationale offers little protection against private drug
testing.

Employees have also challenged workplace drug testing on the

basis of the Vocational Rehabilitation Act of 1973, claiming that drug
addicts are "handicapped people" who may not be discriminated

against162 The Vocational Rehabilitation Act of 1973 prohibits employers who receive federal funds from discriminating against handi-

capped individuals. 63 However, Congress amended this act in 1978 to
further define "handicapped individual" not to include current alcoholic or drug abusers who cannot perform duties or who constitute a
direct threat to the property or safety of others." While the Supreme
Court has commented that Congress did not intend to exclude all
alcoholics and drug addicts under this amendment,

65

any protection

it might have provided in relation to drug testing is severely cur-

tailed. 16

162. See, e.g., National Treasury Employees Union v. Reagon, 685 F. Supp.
1346, 1353 (E.D. La. 1988) ("[allcoholism or other drug abuse are considered
handicapping conditions under [the Act]"), aff'd sub nom. National Treasury Employees Union v. Bush, 891 F.2d 99 (5th Cir. 1989). But see Railway Labor Executives'
Ass'n v. Burnley, 839 F.2d 575, 590 (9th Cir. 1986) ("clear the [nondiscriminatory]
testing regulations are not violative of the Rehabilitation Act"), rev'd sub nom. on
other grounds, Skinner v. Railway Labor Executives' Ass'n, 489 U.S. 602 (1989)
(fourth amendment issue).
163. See Pub. L. No. 93-112, 87 Stat. 355 (1982) (codified as amended at 29
U.S.C.S. §§ 701-796 (Law. Co-op. 1990 & Supp. 1991)).
164. See id.
165. See School Board of Nassau County v. Arline, 480 U.S. 273, 286 n.14
(1987) ("Congress ... instead adopted the Senate proposal excluding only those
alcoholics and drug abusers 'whose current use of alcohol or drugs prevents such
individual from performing the duties of the job in question or whose employment
...would constitute a direct threat to property or the safety of others."') (quoting
29 U.S.C. § 706 and relying on 124 Cong. Rec. 30,322 (1978)).
166. Actions have also been brought under Title VII alleging discriminatory
impact of drug testing programs. See Title VII of the Civil Rights Act of 1964, 42
U.S.C. §§ 2000e-2000e16 (Supp. V 1987) (prohibits employers from discriminating
against employees or applicants on the basis of "race, color, religion, sex, or national
origin"). To prevail in a Title VII case, the employee would have to show that the
employer's drug testing scheme was merely a pretext to allow discrimination against
a protected group. However, Title VII does not specifically address drug testing, and
actions in this context have met with mixed success. Compare Toledo v. Nobel-Sysco,
Inc., 41 Fair Empl. Prac. Cas. (BNA) 282 (D.N.M. 1986) (employer violated Title
VII by refusing to hire religious peyote smoker) with New York City Transit Authority
v. Beazer, 440 U.S. 568 (1979) (allowed exclusion of methadone users, even though
81% affected under policy were black or Hispanic).
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STATE STATUTES

Although employees may have little federal claim to rights regarding drug testing under polygraph or handicap/rehabilitation legislation, many states offer other statutory protection.1 67 Approximately
45 states and the District of Columbia have some type of state
rehabilitation act that protects the handicapped from employment
discrimination. 161 While some states follow the federal rehabilitation
act, many are more liberal in treating substance abuse as a handicap
and may proscribe drug testing. 169 Some states have regulated or
prohibited drug testing specifically. 170 While these states may have
provided a cure for drug testing abuses by employers, the lack of
uniformity and varied interpretation between states has caused excessive litigation and disparities among employees.' 7' Legislation on a
state level also encourages forum shopping and may cause problems
72
with large multi-state corporations.
E.

ANALYSIS OF THE EXISTING LAW

Under the current state of the law, courts have little guidance in
their analysis of the privacy issues implicated in drug testing and the
severe consequences to the employee of an erroneous result. As a
result, the common law is in a state of disarray which is detrimental
to both the private at-will employee and employer.
Courts have often used tenuous rationale to uphold the legality
of drug testing and help fight drug use. 73 For example, the Supreme
167. See K. ZEESE, supra note 7, at § A6-1 (table of state laws).
168. Id. at § 4.02[3].
169. While a review of the individual states is beyond the scope of this comment,
see generally Cecere & Rosen, Legal Implications of Substance Abuse Testing in the
Workplace, 62 NOTRE DAME L. REV. 859, 871 (1987) for a succinct outline of state
statutes.
170. Seven states have passed legislation that regulates drug testing in the private
sector: Connecticut, Iowa, Minnesota, Montana, Rhode Island, Vermont, and Utah.
See Note, Survey of the Law on Employee Drug Testing, 42 U. MiAMi L. REV. 553,
654 (1987) (summarizes laws enacted in each state).
171. See supra notes 135-56 and accompanying text.
172. See Note, Employee Drug-Testing Legislation: Redrawing the Battlelines in
the War on Drugs, 39 STAN. L. REV. 1453, 1453 (1987) (advocating state law solution
to drug testing problem in spite of these drawbacks).
173. See Luedtke v. Nabors Alaska Drilling, 768 P.2d 1123 (Alaska 1989)
(allowing employer to discipline and ultimately discharge employee based upon
urinalysis drug test taken by physician during employee's thirty day vacation period,
where employee had no knowledge that drug test was being performed); Horne v.
J.W. Gibson Well Service Co., 894 F.2d 1194, 1196 (10th Cir. 1990) (ignoring
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Court characterized the privacy interest implicated by a urinalysis as
"minimal" in Skinner.'7 4 This label grossly underestimates the poten-

tial for abuse. 1 5 Skinner involved a public employee being tested
under the NIDA Guidelines which this comment advocates, but even
these guidelines call for a directly observed urination when suspicion
76
is raised as to the integrity of the original unobserved sample.
Especially in the case of a female employee, where this would call for
an eye level observation,'17 this can hardly be categorized as a "minimal" privacy interest.
Another example of a court summarily dismissing an employee's
privacy concerns is demonstrated in the 1989 Alaska Supreme Court
case of Luedtke v. Nabors Alaska Drilling.7 1 In denying Luedtke's
claim for wrongful discharge, the court quoted the Fifth Circuit's
opinion in National Treasury Employees Union v. Von Raab'7 9 saying:
"Finding an objectively reasonable expectation of privacy in urine, a
waste product, contains inherent contradictions."' 80 The court confused the distinction between property and privacy interests, and
ended its analysis of the employee's privacy interests with the concluplaintiff's argument concerning violation of public policy when employer unreasonably invaded privacy: "plaintiff has not shown public policy prohibits employers
from ensuring a drug-free workplace"); Peranzo v. Coughlin, 608 F. Supp. 1504,
1514 (S.D.N.Y. 1985) (allowed unconfirmed EMIT test, notwithstanding manufacturer's own warning: "The inclusion of [the manufacturer's] recommendation, however, by no means renders the unconfirmed use of the EMIT test an unreliable
procedure to follow.").
174. Skinner v. Railway Labor Executives' Ass'n, 489 U.S. 602, 627 (1989). But
see supra note 120 and accompanying text for discussion of this characterization.
175. While the Supreme Court may have reached the correct result in this case,
they refused to properly balance the interests involved and weigh the employee's
privacy interest against the employer's interest in a safe and efficient workplace. The
Court never examined other methods of obtaining the employer's objectives, nor did
it examine what privacy interests of the employee were actually implicated. Characterizing the employee's privacy interests as "minimal" does not even look at what
may be involved in the collection process or what the test results can indicate about
non-employment related health matters.
176. See NIDA Guidelines, supra note 64, at § 2.2(0(16).
177. See Scotti, Voluntary Urine Testing of Physicians, 257 J. A.M.A. 3115,

3115 (1987).
178. 768 P.2d 1123 (Alaska 1989).
179. 808 F.2d 1057 (5th Cir. 1987) (denying stay pending appeal), opinion on
appeal, 816 F.2d 170 (5th Cir. 1987), aff'd in part, vacated in part, 489 U.S. 656
(1989).
180. Luedtke v. Nabors Alaska Drilling, 768 P.2d 1123, 1134 (Alaska 1989)
(quoting National Treasury Employees Union v. Von Raab, 808 F.2d 1057, 1061 (5th
Cir. 1987)).
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sion that because urine is a waste product, no privacy interest existed. 8' The fact that urine is a waste product should have absolutely
no bearing on the private information that may be gleaned by analysis
of it. Testing this "waste product" can reveal "whether an employee
is being treated for a heart condition, manic depression, epilepsy,
diabetes, or schizophrenia.'1 2 Would the court condone testing the
"waste product" for diabetes, pregnancy, or epilepsy as well?
What makes Luedtke seem even more contradictory is that the
same court had earlier held in Ravin v. State'83 that the state cannot
constitutionally prohibit the non-commercial use of marijuana in the
home, based upon the individual's privacy right.' 84 While Ravin is
mentioned in Luedtke, 85 the court states that "this [privacy] right
must yield when it ...

interferes in a serious manner with the health,

safety, rights and privileges of others."'18 6 Then the court seems to
take judicial notice that smoking marijuana during an employee's
month away from work will "interfere in a serious manner" with onthe-job safety.'87
It has been suggested that Congress declared a "war" on drugs
in an attempt to curtail civil rights beyond what is normally tolerated
in a "peacetime" situation.'88 This is not to argue for a total ban on
drug testing, but Congress and the courts should at least be realistic
about the interests being weighed.
IV.

RAMIFICATIONS AND PROBLEMS WITH THE STATUS

Quo

There are numerous problems with the existing common law in

the private at-will employee context, and maintaining the status quo

in this area will prolong and exacerbate the situation. Urinalysis drug
testing is unique from other common law in the stigma that attaches
when a test is failed and in the public misperception of test accuracy
and what a "failed" test actually indicates.

181. Id. at 1134-35.
182. See Note, supra note 107, at 1458 n.27 (quoting "Dr. Harold M. Bates, a
chemist with Metpath Laboratories of Teterburo, N.J., which performs drug-test
analyses").

183. 537 P.2d 494 (Alaska 1975).
184. Id. at 511.

185. Luedtke v. Nabors Alaska Drilling, 768 P.2d 1123, 1135-36 (Alaska 1989).
186. Id. at 1135 (quoting Ravin v. State, 537 P.2d 494, 504 (Alaska 1975)).
187. Id. at 1136.
188. See Wisotsky, Crackdown: The Emerging "Drug Exception" to the Bill of
Rights, 38 HASTINGS L.J. 889, 898 (1987) ("If the Bill of Rights, tradition, or

statutory protections stood in the way of the war effort, then they had to go.").
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Courts have traditionally been reluctant to allow scientific evidence into trials because they assume that most lay jurors will
misperceive the purpose or importance of its use and place exaggerated
weight on such evidence. 18 9 "The public perception of scientific measurements is that they are indisputable."'190 While reports conflict, all
commentators would agree that the accuracy of urinalysis tests is
highly dependent on the lab used, technique utilized, and substance
tested for. 91 The problems with traditional medical evaluation of drug
test results, given their inconclusive nature, 192 may be compounded
when a non-medically trained personnel manager chooses labs, techniques, and cut-off values for drug detection, and interprets results. 193
As one commentator stated: "Equipped with a $300 kit, Acme
Company's deputy assistant personnel trainee can go into the rest
room and attempt to become an instant toxicologist.' 94 Given the
present status of the law, this can and will happen with private
employers who have no incentive to pay a higher price for more

accurate results. 95
The public perceives urinalysis drug testing as a scientific, medically tested laboratory technique that is highly accurate. In reality,

189. See Frye v. United States, 293 F. 1013 (D.C. Cir. 1923) (established rule
of when to admit novel scientific evidence); Imwinkelried, The Standardfor Admitting
Scientific Evidence: A Critique from the Perspective of Juror Psychology, 28 VILL.
L. REV. 554, 562 (1983) (claiming that jurors place exaggerated weight and credibility
in scientific processes which they do not understand).
190. Blanke, Accuracy in Urinalysis, in URINE TESTING FOR DRUGS OF ABUSE 43
(1986) (referring to the general public attitude regarding urinalysis and other scientific
methods).
191. While a lengthy diversion into the numerous studies is beyond the scope of
this article, many are conveniently summarized in K. ZEESE, supra note 7, at §
3.01[3]. Reports range from 9.1076 to 81.9%o errors found in various labs studied. Id.
at § 3.01[3][d]. See also Blanke, Accuracy in Urinalysis, in URINE TESTING FOR DRUGS
OF ABUSE 43, 43-44 (1986); Hansen, Caudill & Boone, Crisis in Drug Testing, 253 J.

A.M.A. 2382, 2382 (1985) (blind survey of labs by Centers for Disease Control in
1985, results showed false positives from 0 to 100 percent).
192. See supra notes 12-18 and accompanying text.
193. See Black, supra note 13, at 33 ("controversy surrounding .

.

. reliability

of drug testing data is a function of misuse of terminology, inappropriate application
of technology, and an unrealistic expectation as to what information is provided by
urine drug testing").
194. Rothstein, Screening Workers for Drugs: A Legal and Ethical Framework,
11 EMPLOYEE REL. L.J. 422, 437 (1985-86).
195. See Imwinkelried, Some Preliminary Thoughts on the Wisdom of Governmental Prohibitionor Regulation of Employee Urinalysis Testing, 11 NOVA L. REV.
563, 566-68, 581-82 (1987) (many employers now rely on unconfirmed tests and select
inferior testing labs based on strictly price considerations).
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many drug testing manufacturers market "field kits" to be used96 by
lay people away from the laboratories with little or no training1
Unlike private employers, an employee will likely pay an exorbitantly high price for inaccurate test results. Being terminated from a
job due to "failing" a drug test can result in stigma that follows the
employee much farther than the immediate relation.1' 9 Many private
companies do not bother to utilize confirmatory testing even though
adverse action may be taken against the employee based on the
results. 98 This practice is certain to produce false accusations of drug
abuse, and the consequences may be devastating to an employee's
professional career. An expert responding to a recent Journal of
American Medical Association wrote: "It is almost beyond my ability
to comprehend the fact that organizations are actually basing employee life-career decisions upon a single EMIT or RIA result."',
Public policy reasons support a desire to ensure fair and accurate
drug testing. This public policy involves concerns of employee coercion
and discrimination and public costs of welfare and unemployment.
Allowing employers to use cheap, inaccurate tests actually shifts the
burden of the employer's activity over to society in general. The
public bears the cost through welfare programs and unemployment
compensation of relocating ex-employees stigmatized as "drug addicts" for failing inaccurate drug tests or failing drug tests as the
result of lab errors.
The employment at will doctrine which allows employers nearly
unlimited discretion is based on the "voluntariness" of the employee.
Theoretically, an employee can simply go elsewhere and choose a job
that does not require drug testing. However, this notion "underestimates the employee's need to earn a living and . . . misunderstands
the economic realities facing most employees." ' 200 It also ignores the
employee's unequal bargaining power. The fact that most jurisdictions
196. See Rothstein, supra note 194, at 437 (EMIT kit under $300); McGovern,
Employee Drug-Testing Legislation: Redrawing the Battlelines in the War on Drugs,
39 STAN. L. REV. 1453, 1458 n.30 (1987) (Abuscreen System kit costing $228).
197. The failure may make subsequent employment difficult to obtain if reference calls are made to ascertain the terms of discharge, and it may ruin the exemployee's reputation with previous co-workers.
198. See supra note 22 and accompanying text.
199. Hoyt, Finnigan, Nee, Shults & Butler, Drug Testing in the WorkplaceAre Methods Legally Defensible?, 258 J. A.M.A. 504, 507 (1987) (quoting survey
respondent).
200. See Note, Drug Testing of Public and Private Employees in Alaska, 5
L. REV. 133, 148 n. 117 (1988) (courts have incorrectly relied on "voluntari-

ALASKA

ness" of employee drug testing).
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have relaxed the employee at will doctrine suggests that the economic
situation facing the modern employee does not correspond with the
voluntariness theory, and the public policies that supported the strict
at-will doctrine are now becoming obsolete.2 °'
Maintaining the status quo will also hamper efforts of Congress
in eliminating discrimination. While numerous laws exist to preclude
discriminatory practices in employment, totally unrestrained drug
testing may be used as a pretext to legitimatize otherwise invalid
hiring/firing decisions. An employer under today's law is allowed
virtually unlimited discretion to refuse to hire or discharge to an
employee under the pretext of promoting a safe and drug-free workplace. 20 2 Thus, groups that are historically the targets of illegal discrimination in employment may be now open to a new, socially
acceptable, and legal form of discrimination. Some form of regulation
is definitely needed in order to ensure fair compliance with existing
anti-discriminatory regulations.
V.

RECOMMENDATION

Applying the NIDA guidelines to private employers who choose
to use drug testing would promote the societal interest of fighting our
drug problem while maintaining responsibility in employment decisions. Employers do have a legitimate interest in keeping the workplace drug-free, as well as a responsibility to others to provide a safe
workplace. This legislation would allow them to pursue that goal
while protecting employees from the unneccessary stigmatization resulting from arbitrary or discriminatory uses of drug testing. The
NIDA guidelines ensure employees that they will be treated fairly
when submitting to a urinalysis test and that state-of-the-art procedures will be used. 20 3 This federal legislative proposal would provide
201. See supra note 106 and accompanying text. See also K. ZEESE, supra note
7, at § 4.01 (discussing how the common law has moved away from strict "at-will"
doctrine).
202. See Glasser, supra note 96, at 80 (The author, who is the Executive Director
of the American Civil Liberties Union, states that this situation is already occurring.
He mentions a Georgia "whistleblower" who was subsequently "reported" anony-

mously on a company drug hot line. This employee was tested and fired but not
permitted to see her test results.).

203. See Mandatory Guidelines for Federal Workplace Drug Testing Programs,

53 Fed. Reg. 11,970 (1988). These guidelines mandate that all urinalysis drug testing

will be performed under rigid conditions; tests will be confirmed by gas chromatography/mass spectrometry; and results will be reviewed by a medical officer before
any action is taken after a failed test. Id.
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solutions to both the employers' and employees' concerns, and would
be much more efficient and effective than waiting for the courts to
solidify this area of law on a case-by-case basis.
Adopting the NIDA guidelines would also allow for flexibility as
drug testing technology continues. As drug testing is a relatively new
science and is still rapidly developing, it would make little sense to
"freeze" the technology in its present state by a statute. Entrusting
an agency such as NIDA to promulgate regulations in an area of
science like drug testing would avoid suspending technology while still
ensuring that any new developments will be properly tested and
certified as accurate before being applied to innocent employees. With
the amount of research that NIDA already performs and the certification process that it has already set up for federal labs, adopting the
guidelines for private labs is an efficient use of resources to solve a
societal problem.
While some commentators are opposed to federal regulation of
the private drug testing market, 2°4 the extent of the problem is not
merely "private" and federal regulation is justified. The costs of
welfare or rehabilitation are directly borne by society, and public
policy strongly suggests that regulation is needed in this area.
VI.

CONCLUSION

Drug testing has become a major tool by which employers seek
to maintain a safe, dependable, and efficient work force. It has a
legitimate purpose and many benefits to offer. Employers and employees alike have an interest in a safe, drug-free workplace. However,
allowing private companies to conduct urinalysis drug testing totally
unregulated may result in needless stigmatization of employees and
may actually impose unneccessary costs in reaching the goal of a
"drug-free workplace" on society. While employers have a legitimate
interest in controlling the workplace, this interest should be circumscribed to protect the employees' interest in fair treatment.
Adopting the NIDA guidelines would ensure fairness in the
workplace and benefit all concerned. Employees would have the
benefit of a safe workplace and fair treatment, while employers would
be able to protect their business interests. The guidelines represent a
fair compromise to both the employer and employee.
SHANE J. OSOWSKI

204. See Strasser, Drug Testing Requires Examination of Methods, Reasons,
and Usefulness, OCCUPATIONAL HEALTH & SAFETY, June 1990, at 52 (fearing more
burdensome rules and regulations).

